Open AccessIn Vitro Antituberculosis Activities of ACH-702, a Novel Isothiazoloquinolone, against Quinolone-Susceptible and Quinolone-Resistant Isolates
Author(s) -
Michael J. Pucci,
Maria Ackerman,
Jane A. Thanassi,
Carolyn Shoen,
Michael H. Cynamon
Publication year - 2010
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00287-10
Subject(s) - quinolone , moxifloxacin , dna gyrase , microbiology and biotechnology , in vitro , mycobacterium tuberculosis , ofloxacin , in vivo , antibacterial agent , biology , staphylococcus aureus , antibacterial activity , antibiotics , tuberculosis , pharmacology , bacteria , medicine , ciprofloxacin , escherichia coli , biochemistry , genetics , pathology , gene
ACH-702 is a new isothiazoloquinolone with potentin vitro andin vivo activities against important bacterial pathogens, includingStaphylococcus aureus. In this study, ACH-702 was found to have promisingin vitro antibacterial activity againstMycobacterium tuberculosis , with MICs of ≤1 μg/ml, comparable to that of the fluoroquinolone moxifloxacin for quinolone-susceptible isolates but superior to that for quinolone-resistant isolates. Biochemical assays involvingM. tuberculosis gyrase enzymes indicated that ACH-702 had significantly improved inhibitory activity compared with fluoroquinolones.